148 related articles for article (PubMed ID: 31821222)
1. Drug-Drug Interactions (DDIs) in Psychiatric Practice, Part 7: Relative Receptor Binding Affinity as a Way of Understanding the Differential Pharmacology of Currently Available Antipsychotics.
Preskorn SH
J Psychiatr Pract; 2019 Nov; 25(6):461-465. PubMed ID: 31821222
[TBL] [Abstract][Full Text] [Related]
2. Drug-Drug Interactions (DDIs) in Psychiatric Practice, Part 8: Relative Receptor Binding Affinity as a Way of Understanding the Differential Pharmacology of Currently Available Antidepressants.
Preskorn SH
J Psychiatr Pract; 2020 Jan; 26(1):46-51. PubMed ID: 31913969
[TBL] [Abstract][Full Text] [Related]
3. Drug-Drug Interactions (DDIs) in Psychiatric Practice, Part 9: Interactions Mediated by Drug-metabolizing Cytochrome P450 Enzymes.
Preskorn SH
J Psychiatr Pract; 2020 Mar; 26(2):126-134. PubMed ID: 32134885
[TBL] [Abstract][Full Text] [Related]
4. Drug-Drug Interactions (DDIs) in Psychiatric Practice, Part 6: Pharmacodynamic Considerations.
Preskorn SH
J Psychiatr Pract; 2019 Jul; 25(4):290-297. PubMed ID: 31291209
[TBL] [Abstract][Full Text] [Related]
5. Drug-Drug Interactions (DDIs) in Psychiatric Practice, Part 5: Major Types of Pharmacodynamic DDIs Based on Mechanism of Action (With Updated Neuroscience-based Nomenclature).
Preskorn SH; Germann A
J Psychiatr Pract; 2019 May; 25(3):206-211. PubMed ID: 31083033
[TBL] [Abstract][Full Text] [Related]
6. Drug-Drug Interactions (DDIs) in Psychiatric Practice, Part 2: Strategies to Minimize Adverse Outcomes From Unintended DDIs.
Preskorn SH
J Psychiatr Pract; 2018 Sep; 24(5):341-347. PubMed ID: 30427821
[TBL] [Abstract][Full Text] [Related]
7. Drug-drug Interactions in Psychiatric Practice, Part 4: Classification of Neuropsychiatric Medications Based on Their Principal Mechanisms of Action (With Updated Neuroscience-based Nomenclature).
Preskorn SH; Germann A
J Psychiatr Pract; 2019 Mar; 25(2):118-127. PubMed ID: 30849059
[TBL] [Abstract][Full Text] [Related]
8. Drug-drug Interactions in Psychiatric Practice, Part 1: Reasons, Importance, and Strategies to Avoid and Recognize Them.
Preskorn SH
J Psychiatr Pract; 2018 Jul; 24(4):261-268. PubMed ID: 30427809
[TBL] [Abstract][Full Text] [Related]
9. Drug-Drug Interactions (DDIs) in Psychiatric Practice, Part 3: Pharmacokinetic Considerations.
Preskorn SH
J Psychiatr Pract; 2019 Jan; 25(1):34-40. PubMed ID: 30633730
[TBL] [Abstract][Full Text] [Related]
10. Potential drug-drug interactions and polypharmacy in institutionalized elderly patients in a public hospital in Brazil.
Castilho ECD; Reis AMM; Borges TL; Siqueira LDC; Miasso AI
J Psychiatr Ment Health Nurs; 2018 Feb; 25(1):3-13. PubMed ID: 28892271
[TBL] [Abstract][Full Text] [Related]
11. Why Are Patients With COVID-19 at Risk for Drug-Drug Interactions?
Preskorn SH; Quadri S
J Psychiatr Pract; 2020 Nov; 26(6):485-492. PubMed ID: 33275385
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of QT interval prolonging drug-drug interactions (QT-DDIs) in psychiatry wards of tertiary care hospitals in Pakistan: a multicenter cross-sectional study.
Khan Q; Ismail M; Haider I; Khan F
Int J Clin Pharm; 2017 Dec; 39(6):1256-1264. PubMed ID: 28895028
[TBL] [Abstract][Full Text] [Related]
13. Consistency of psychotropic drug-drug interactions listed in drug monographs.
Liu X; Hatton RC; Zhu Y; Hincapie-Castillo JM; Bussing R; Barnicoat M; Winterstein AG
J Am Pharm Assoc (2003); 2017; 57(6):698-703.e2. PubMed ID: 28844584
[TBL] [Abstract][Full Text] [Related]
14. Prevalence and risk of potential cytochrome P450-mediated drug-drug interactions in older hospitalized patients with polypharmacy.
Doan J; Zakrzewski-Jakubiak H; Roy J; Turgeon J; Tannenbaum C
Ann Pharmacother; 2013 Mar; 47(3):324-32. PubMed ID: 23482734
[TBL] [Abstract][Full Text] [Related]
15. Polypharmacy in patients with advanced cancer and pain: a European cross-sectional study of 2282 patients.
Kotlinska-Lemieszek A; Paulsen O; Kaasa S; Klepstad P
J Pain Symptom Manage; 2014 Dec; 48(6):1145-59. PubMed ID: 24780183
[TBL] [Abstract][Full Text] [Related]
16. Quantifying the impact of drug-drug interactions associated with opioids.
Pergolizzi JV
Am J Manag Care; 2011 Sep; 17 Suppl 11():S288-92. PubMed ID: 21999761
[TBL] [Abstract][Full Text] [Related]
17. Polypharmacy and severe potential drug-drug interactions among older adults with cardiovascular disease in the United States.
Sheikh-Taha M; Asmar M
BMC Geriatr; 2021 Apr; 21(1):233. PubMed ID: 33827442
[TBL] [Abstract][Full Text] [Related]
18. Identifying and Communicating Clinically Meaningful Drug-Drug Interactions.
Nelson SD; LaFleur J; Hunter E; Archer M; Steinvoort C; Maden C; Oderda GM
J Pharm Pract; 2016 Apr; 29(2):110-5. PubMed ID: 25107417
[TBL] [Abstract][Full Text] [Related]
19. Drug interactions in dying patients: a retrospective analysis of hospice inpatients in Germany.
Frechen S; Zoeller A; Ruberg K; Voltz R; Gaertner J
Drug Saf; 2012 Sep; 35(9):745-58. PubMed ID: 22809376
[TBL] [Abstract][Full Text] [Related]
20. Statin drug interactions and related adverse reactions: an update.
Bellosta S; Corsini A
Expert Opin Drug Saf; 2018 Jan; 17(1):25-37. PubMed ID: 29058944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
